In contrast, daily administration of roxadustat, which was recently approved for the treatment of renal anemia in patients with chronic kidney disease, abolished hypertension and organ injury induced by Ang II (Yu et al., 2021). This evidence concerns the gene AGT and hypertensive disorder.